In a world still reeling from the logistical nightmare of mRNA cold chains, CyanVac is playing a different game entirely. They aren't chasing the latest RNA tech; they're resurrecting a forgotten virus to make vaccines as easy to administer as a nasal spray.

"CyanVac isn't just making vaccines; they're solving the cold-chain problem with a virus that hasn't been in the spotlight for decades."

The data reveals a company in its infancy but with a focused strategy. Their traffic profile—48% direct, 25% organic—indicates low brand awareness but high intent among those who do find them. The top keyword 'cyanvac address' suggests investors and partners are actively digging for contact info, a sign of inbound interest despite their stealthy footprint. However, the 'undefined' top countries in their analytics hint at a lack of sophisticated geo-targeting or a truly global reach at this stage.

• **Needle-Free Administration:** Eliminates needle anxiety and the need for trained medical personnel for administration.
• **Thermal Stability:** PIV5-based vaccines are inherently more stable than mRNA, drastically reducing distribution costs.
• **Mucosal Immunity:** Intranasal delivery targets IgA antibodies in the respiratory tract, potentially blocking transmission at the source.